March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Correlation of Retinal Morphology and Visual Acuity in the Comparison of Age-Related Macular Degeneration Treatment Trial (CATT)
Author Affiliations & Notes
  • Glenn J. Jaffe
    Ophthalmology, Duke University Eye Center, Durham, North Carolina
  • Maureen G. Maguire
    Ophthalmology, University of Pennsylvania, Philadelphia, Pennsylvania
  • Cynthia A. Toth
    Ophthalmology, Duke Univ Eye Center, Durham, North Carolina
  • Gui-Shuang Ying
    Ophthalmology, Scheie Eye Institute, Philadelphia, Pennsylvania
  • Jiayan Huang
    Ophthalmology, University of Pennsylvania, Philadelphia, Pennsylvania
  • Ebenezer Daniel
    Ophthalmology, University of Pennsylvania, Philadelphia, Pennsylvania
  • Juan E. Grunwald
    Ophthal-Scheie Eye Inst, Univ of Pennsylvania, Philadelphia, Pennsylvania
  • Daniel F. Martin
    Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio
  • CATT Study Group
    Ophthalmology, Duke University Eye Center, Durham, North Carolina
  • Footnotes
    Commercial Relationships  Glenn J. Jaffe, None; Maureen G. Maguire, None; Cynthia A. Toth, Alcon, Bioptigen, both unlicensed (P), Bioptigen, Genentech (F), Physical Sciences Incorporated (C); Gui-Shuang Ying, None; Jiayan Huang, None; Ebenezer Daniel, None; Juan E. Grunwald, None; Daniel F. Martin, None
  • Footnotes
    Support  5U10-EY-017825-06
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 2893. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Glenn J. Jaffe, Maureen G. Maguire, Cynthia A. Toth, Gui-Shuang Ying, Jiayan Huang, Ebenezer Daniel, Juan E. Grunwald, Daniel F. Martin, CATT Study Group; Correlation of Retinal Morphology and Visual Acuity in the Comparison of Age-Related Macular Degeneration Treatment Trial (CATT). Invest. Ophthalmol. Vis. Sci. 2012;53(14):2893.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : The morphologic patterns after treatment with the VEGF drugs ranibizumab (L) and bevacizumab (A) and the relationship of the morphologic features with visual acuity (VA), and whether it is necessary to eliminate all excess fluid to achieve optimal VA, are not well understood. We describe the effect of different anti-VEGF treatment strategies on lesion activity, as measured by OCT and FA, and visual acuity outcomes in CATT.

Methods: : Stratus OCT, obtained at baseline and at monthly intervals through wk 52, and FA obtained at baseline and wk 52 from 1185 subjects were interpreted by centralized Reading Centers. The frequency of OCT-determined intraretinal fluid (IRF), subretinal fluid (SRF), and subRPE fluid (SRPEF), retinal and subretinal thickness, and FA-determined leakage, stratified by treatment group (L and A, monthly or PRN) was correlated with VA.

Results: : Fluid of all 3 types (IRF, SRF, SRPEF) and retinal and subretinal tissue thickness, decreased in all 4 treatment groups throughout the study. More eyes treated with L than A had no fluid at 52 wks; however, the majority of eyes (55% in L monthly, 74-80% in other groups) still had fluid, most commonly IRF (37-58%), at 1 year. In all treatment groups, average VA increased by wk 52, but at all time points, eyes with residual IRF, and not those with SRF or SRPEF, had worse mean VA (6 to 7 letters). Retinal thickness decreased markedly by 4 weeks, with the greater mean decrease in L eyes (155 u) compared to A eyes (127 u) and lowest mean thickness at 1 year (266 u) with L monthly than with the other treatments (294-308 u). VA and intraretinal thickness were not related linearly, ie, eyes with abnormally thin (<120 u) or thick (>212u) retinas had worse VA than those with normal thickness (120-212 u). At wk 52, larger CNV lesions had worse VA, (r=-0.25), and eyes with monthly treatment had smaller CNV area than those on PRN treatment.

Conclusions: : Anti-VEGF therapy reduces CNV lesion activity and improves VA in all treatment groups, but at all time points those with residual IRF had worse VA than those without. Abnormally thin or thick retinas had worse VA. Monthly L dosing yielded more eyes with no fluid and lower mean retinal thickness, although the long-term significance is yet unknown. These results have important treatment implications in eyes undergoing anti-VEGF therapy for NVAMD.

Clinical Trial: : http://www.clinicaltrials.gov NCT00593450

Keywords: AIDS/HIV • imaging methods (CT, FA, ICG, MRI, OCT, RTA, SLO, ultrasound) • visual acuity 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×